What is hormone therapy

Hormone therapy for menopausal symptoms

Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; (3): CD002229.

Federal Institute for Drugs and Medical Devices (BfArM). Further drug risks: BfArM informs about new results on hormone therapy with tibolone after the menopause. 05/01/2005.

German Society for Gynecology and Obstetrics (DGGG), Austrian Society for Gynecology and Obstetrics (OEGGG), Swiss Society for Gynecology and Obstetrics (SGGG). Peri- and postmenopause diagnostics and interventions (S3 guideline). AWMF registration number: 015-062. 01.2020.

Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016; (10): CD008536.

Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012; (8): CD000402.

Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C et al. Menopausal Symptoms: Comparative Effectiveness of Therapies. 03.2015. (AHRQ Comparative Effectiveness Reviews; Volume 147).

Lethaby A, Ayeleke RO, Roberts H. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; (8): CD001500.

MacLennan AH, Broadbent JL, Lester S, Moore V. Oral estrogen and combined estrogen / progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; (4): CD002978.

Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017; (1): CD004143.

Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291 (13): 1610-1620.

Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294 (2): 183-193.

Robert Koch Institute (RKI), Federal Statistical Office (Destatis). Hormone therapy in (post-) menopausal women in Germany 2007. Study results on benefits, risks and the reality of care (health reporting of the federal government). Berlin: RKI; 2008.

Whelan AM, Jurgens TM, Trinacty M. Defining bioidentical hormones for menopause-related symptoms. Pharm Pract (Granada) 2011; 9 (1): 16-22.

IQWiG health information is intended to help understand the advantages and disadvantages of important treatment options and health care offers.

Whether one of the options we have described actually makes sense in individual cases can be clarified in a conversation with a doctor. Gesundheitsinformation.de can support the discussion with doctors and other experts, but not replace it. We do not offer individual advice.

Our information is based on the results of high quality studies. They are created by a team of authors from medicine, science and the editorial team and reviewed by experts outside of IQWiG. In our methods, we describe in detail how we develop our texts and keep them up to date.